Amfepramonum [INN-Latin] en es it fr

Amfepramonum [INN-Latin] Brand names, Amfepramonum [INN-Latin] Analogs

Amfepramonum [INN-Latin] Brand Names Mixture

  • No information avaliable

Amfepramonum [INN-Latin] Chemical_Formula


Amfepramonum [INN-Latin] RX_link

Amfepramonum [INN-Latin] fda sheet

Amfepramonum_[INN-Latin] FDA

Amfepramonum [INN-Latin] msds (material safety sheet)

Amfepramonum_[INN-Latin] MSDS

Amfepramonum [INN-Latin] Synthesis Reference

No information avaliable

Amfepramonum [INN-Latin] Molecular Weight

205.296 g/mol

Amfepramonum [INN-Latin] Melting Point

No information avaliable

Amfepramonum [INN-Latin] H2O Solubility

No information avaliable

Amfepramonum [INN-Latin] State

No information avaliable

Amfepramonum [INN-Latin] LogP


Amfepramonum [INN-Latin] Dosage Forms

25 mg tablets and 75 mg controlled-release tablets.

Amfepramonum [INN-Latin] Indication

Used in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction.

Amfepramonum [INN-Latin] Pharmacology

Diethylpropion is a sympathomimetic stimulant drug marketed as an appetite suppressant. Chemically, it is the N,N-diethyl analog of cathinone. Its mechanism of action is similar to other appetite suppressants such as sibutramine, phentermine and dextroamphetamine.

Amfepramonum [INN-Latin] Absorption

Diethylpropion is rapidly absorbed from the GI tract after oral administration.

Amfepramonum [INN-Latin] side effects and Toxicity

The reported oral LD50 for mice is 600 mg/kg, for rats is 250 mg/kg and for dogs is 225 mg/kg. Manifestation of acute overdosage include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, and panic states.

Amfepramonum [INN-Latin] Patient Information

No information avaliable

Amfepramonum [INN-Latin] Organisms Affected

Humans and other mammals